We welcome requests for further information or interviews.
Robert Robinson Avenue
The Oxford Science Park
Circassia is a world-class specialty pharmaceutical business focused on respiratory disease. Circassia sells its novel, market-leading NIOX® asthma management products directly to specialists in the United States, United Kingdom, China and Germany, and in a wide range of other countries through its network of partners. In 2017, the Company established a collaboration with AstraZeneca in the US in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza®. The Company has the commercial rights to the NDA-stage COPD product Duaklir®*, and following the exercise of its option anticipates taking full commercial control of Tudorza® in the US in 2019. Circassia also has the commercial rights to the late-stage ventilator-compatible nitric oxide product AirNOvent** in the United States and China.
*The Duaklir® trademark is registered in the United States; the mark is not currently approved for use by the FDA.
**AirNOvent is not an approved name for the product and may not be the final name submitted for approval.
Circassia Pharmaceuticals plc may use your personal information to contact you by email, telephone or post to respond to your query.